#5 - Pfizer (NYSE:PFE)
Whether you have gotten the Covid-19 vaccine or not, there’s no denying that Pfizer (NYSE:PFE) was one of the hottest stocks of 2020. And with the likelihood of booster shots being required in the U.S., the possibility of vaccinating young children, as well as the increasing demand for vaccines throughout the world, 2021 should be another year that growth and income investors should benefit from PFE stock.
Pfizer stock is flat for 2021 and prior to the release of its vaccine, it was struggling to make up for its pandemic drop. Keep in mind that some of Pfizer’s business was affected by the pandemic. However, that should continue to mitigate in 2021 which should provide some added revenue to support the company’s dividend.
The company is not yet part of the Dividend Aristocrat club having only increased its dividend since 2010. However, Pfizer’s dividend payout ratio sits at 4.04% which is well above the S&P 500 average of 1.8%.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $28.66
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $35.86 (25.1% Upside)
